Sökning: WFRF:(Cwikla Jaroslaw B)
> Öberg Kjell 1946 >
Blood Chromogranin ...
Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms
-
- Matar, Somer (författare)
- Wren Labs, Branford, CT USA.
-
- Malczewska, Anna (författare)
- Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA.;Med Univ Silesia, Dept Endocrinol & Neuroendocrine Tumors, Katowice, Poland.
-
- Öberg, Kjell, 1946- (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
visa fler...
-
- Bodei, Lisa (författare)
- Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA.
-
- Aslanian, Harry (författare)
- Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA.
-
- Lewczuk-Myslicka, Anna (författare)
- Med Univ Gdansk, Dept Endocrinol & Internal Med, Gdansk, Poland.
-
- Filosso, Pier Luigi (författare)
- Univ Turin, Dept Thorac Surg, Turin, Italy.
-
- Suarez, Alejandro L. (författare)
- Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA.
-
- Kolasinska-Cwikla, Agnieszka (författare)
- Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland.
-
- Roffinella, Matteo (författare)
- Univ Turin, Dept Thorac Surg, Turin, Italy.
-
- Kos-Kudla, Beata (författare)
- Med Univ Silesia, Dept Endocrinol & Neuroendocrine Tumors, Katowice, Poland.
-
- Cwikla, Jaroslaw B. (författare)
- Univ Warmia & Mazury, Dept Radiol, Olsztyn, Poland.
-
- Drozdov, Ignat A. (författare)
- Wren Labs, Branford, CT USA.
-
- Kidd, Mark (författare)
- Wren Labs, Branford, CT USA.
-
- Modlin, Irvin M. (författare)
- Yale Univ, Sch Med, Gastroenterol & Endoscop Surg, New Haven, CT USA.
-
visa färre...
-
Wren Labs, Branford, CT USA Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA.;Med Univ Silesia, Dept Endocrinol & Neuroendocrine Tumors, Katowice, Poland. (creator_code:org_t)
- 2019-04-16
- 2020
- Engelska.
-
Ingår i: Neuroendocrinology. - : S. Karger AG. - 0028-3835 .- 1423-0194. ; 110:3-4, s. 185-197
- Relaterad länk:
-
https://www.karger.c...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Identification of circulating tumor markers for clinical management in bronchopulmonary (BP) neuroendocrine tumors/neoplasms (NET/NEN) is of considerable clinical interest. Chromogranin A (CgA), a "universal" NET biomarker, is considered controversial as a circulating biomarker of BPNEN.Aim: Assess utility of CgA in the diagnosis and management of BPNEN in a multicentric study.Material and Methods: CgA diagnostic metrics were assessed in lung NET/NENs (n = 200) and controls (n = 140), randomly assigned to a Training and Test set (100 BPC and 70 controls in each). Assay specificity was evaluated in neoplastic lung disease (n = 137) and nonneoplastic lung disease (n = 77). CgA efficacy in predicting clinical status was evaluated in the combined set of 200 NET/NENs. CgA levels in bronchopulmonary neuroendocrine tumor (BPNET) subtypes (atypical [AC] vs. typical [TC]) and grade was examined. The clinical utility of an alteration of CgA levels (+/- 25%) was evaluated in a subset of 49 BPNET over 12 months. CgA measurement was by NEOLISA(TM) kit (EuroDiagnostica).Results: Sensitivity and specificity in the training set were 41/98%, respectively. Test set data were 42/87%. Training set area under receiver operator characteristic analysis differentiated BPC from control area under the curve (AUC) 0.61 +/- 0.05 p = 0.015. Test set the data were AUC 0.58 +/- 0.05, p = 0.076. In the combined set (n = 200), 67% BPNET/NEN (n = 134) had normal CgA levels. CgA levels did not distinguish histological subtypes (TC vs. AC, AUC 0.56 +/- 0.04, p = 0.21), grade (p = 0.45-0.72), or progressive from stable disease (AUC 0.53 +/- 0.05 p = 0.47). There was no correlation of CgA with Ki-67 index (Pearson r = 0.143, p = 0.14). For nonneoplastic diseases (chronic obstructive pulmonary disorder and idiopathic pulmonary fibrosis), CgA was elevated in 26-37%. For neoplastic disease (NSCLC, squamous cell carcinoma), CgA was elevated in 11-16%. The neuroendocrine SCLC also exhibited elevated CgA (50%). Elevated CgA was not useful for differentiating BPNET/NEN from these other pathologies. Monitoring BPNET/NEN over a 12-month period identified neither CgA levels per se nor changes in CgA were reflective of somatostatin analog treatment outcome/efficacy or the natural history of the disease (progression).Conclusions: Blood CgA levels are not clinically useful as a biomarker for lung BPNET/NEN. The low specificity and elevations in both nonneoplastic as well as other common neoplastic lung diseases identified limited clinical utility for this biomarker.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Bronchopulmonary
- Lung
- Chromogranin A
- Biomarker
- Carcinoid
- Diagnosis
- Prognosis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Matar, Somer
-
Malczewska, Anna
-
Öberg, Kjell, 19 ...
-
Bodei, Lisa
-
Aslanian, Harry
-
Lewczuk-Myslicka ...
-
visa fler...
-
Filosso, Pier Lu ...
-
Suarez, Alejandr ...
-
Kolasinska-Cwikl ...
-
Roffinella, Matt ...
-
Kos-Kudla, Beata
-
Cwikla, Jaroslaw ...
-
Drozdov, Ignat A ...
-
Kidd, Mark
-
Modlin, Irvin M.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Neuroendocrinolo ...
- Av lärosätet
-
Uppsala universitet